Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899764 | 0.83 | GABRG2 (0.38) | P2RX7PTGS1PTGS2CYP11B2CYP2D6 | |
| SCHEMBL898846 | 0.83 | MARS1 (0.38) | P2RX7PTGS1PTGS2CYP11B2CYP2D6 | |
| SCHEMBL899733 | 0.78 | GABRA2 (0.47) | CYP2D6SMN1; SMN2 | |
| SCHEMBL899870 | 0.70 | GABRG2 (0.35) | CES2CES1PTGS1PTGS2CYP11B2 | |
| SCHEMBL899066 | 0.68 | MAPK14 (0.37) | HTTCES2CES1P2RX7MAPK14 | |
| SCHEMBL1726706 | 0.68 | PTPN11 (0.40) | HTTCES2CES1P2RX7MAPK14 | |
| SCHEMBL13291390 | 0.67 | CES2 (0.74) | HTTCES2CES1MAPK14RAB9A | |
| SCHEMBL10627251 | 0.66 | EGFR (0.52) | HTTCES2CES1MAPK14KDM4E | |
| SCHEMBL2549470 | 0.64 | NOTUM (0.49) | P2RX7 | |
| SCHEMBL2861947 | 0.64 | HPGD (0.61) | CES2CES1P2RX7MAPK14HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621907-A1 | FUNGICIDAL IMIDAZOLES | E.I. Du Pont De Nemours And Company (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | EI DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012044650-A1 | FUNGICIDAL IMIDAZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | CYP1A1, CYP1B1, CYP2E1 | HTT 4059/4885CES2 1120/4885CES1 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.